| URL | https://www.fiercepharma.com/manufacturing/reopeni |
| Source | Fierce Pharma |
| Date Published | 08/30/2022 |
| Author Name | Kevin Dunleavy |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Jackson Healthcare |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2022 |
| State(s) reshored to: | TN |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | penicillin |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption risk/Natural disaster risk/Political instability |
| What domestic positive factors made reshoring more attractive? | Image/brand, Other, COVOD-19 |